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Abstract
Addback of donor T cells following T cell-depleted stem cell transplantation (SCT) can accelerate
immune reconstitution and be effective against relapsed malignancy. After haploidentical SCT, a
high risk of graft-versus-host disease (GVHD) essentially precludes this option, unless the T cells
are first depleted of alloreactive precursor cells. Even then, the risks of severe GVHD remain
significant. To increase the safety of the approach and thereby permit administration of larger T cell
doses, we used a suicide gene, inducible caspase 9 (iCasp9), to transduce allodepleted T cells,
permitting their destruction should administration have adverse effects. We made a retroviral vector
encoding iCasp9 and a selectable marker (truncated CD19). Even after allodepletion (using anti-
CD25 immunotoxin), donor T cells could be efficiently transduced, expanded, and subsequently
enriched by CD19 immunomagnetic selection to >90% purity. These engineered cells retained anti-
viral specificity and functionality, and contained a subset with regulatory phenotype and function.
Activating iCasp9 with a small-molecule dimerizer rapidly produced >90% apoptosis. Although
transgene expression was downregulated in quiescent T cells, iCasp9 remained an efficient suicide
gene, as expression was rapidly upregulated in activated (alloreactive) T cells. We have demonstrated
the clinical feasibility of this approach after haploidentical transplantation by scaling up production
using clinical grade materials.
INTRODUCTION
Donor T cell infusion is an effective strategy for conferring anti-viral and anti-tumor immunity
following allogeneic stem cell transplantation1-3. This can be particularly useful in T cell
depleted transplantation, where immune reconstitution is delayed. In haploidentical
transplantation, the need to accelerate immune reconstitution is most pressing; here, profound
immune deficiency as a consequence of vigorous T cell depletion and MHC-incompatibility,
results in high rates of infectious complications and disease relapse4,5. Unfortunately however,
addback of unmanipulated donor T cells is unlikely to be feasible in the haploidentical setting
because graft-versus-host disease (GVHD) can occur after addback of as few as 3×104
CD3+ cells /kg6. This problem can be partially overcome by selective depletion of alloreactive
cells, for example by using immunotoxins directed to activation markers on alloreactive
cells7-9. We, and others, have previously shown that addback of allodepleted T cells at doses
between 1 to 8×105 cells /kg is associated with a low incidence of GVHD and significantly
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accelerates T cell recovery and reconstitutes anti-viral immunity7,8. However, disease relapse
remains high in these series, and since the estimated frequency of tumor-reactive precursors is
1 to 2 logs less than frequency of viral-reactive precursors10,11, much greater dose escalation
is likely required to reconstitute anti-tumor immunity.
While dose escalation of allodepleted T cells may be desirable, it may not be safe. The risk of
GVHD increases with increasing T cell dose12, and the maximum dose that can be safely
infused in any given individual cannot be predicted with certainty. Once established, severe
GVHD unresponsive to frontline therapy has a poor prognosis. Hence, although severe GVHD
occurs infrequently, the fact that it is unpredictable and may be fatal compromises dose
intensity in all patients. Suicide gene-modification of T cells circumvents this biological
uncertainty: effective T cell doses can be administered to all patients safe in the knowledge
that any GVHD that develops can be effectively controlled by activation of the suicide gene
mechanism.
One of the most widely used suicide genes is Herpes simplex virus thymidine kinase (HSVtk).
This enzyme mediates the conversion of ganciclovir to ganciclovir triphosphate which is toxic
to dividing cells; administration of ganciclovir efficiently eliminates HSVtk-modified T cells
and abrogates acute GVHD13-15. Although providing proof of concept of suicide gene
therapy, HSVtk has a number of drawbacks, the most important of which is immunogenicity:
being a foreign protein, HSVtk is a target for CD4 and CD8 T cell-mediated immune response,
which results in premature elimination of HSVtk-modified cells16. Other drawbacks of HSVtk
include restriction of killing to dividing cells, the unintended elimination of gene-modified
cells when ganciclovir is used for treatment of cytomegalovirus (CMV) reactivation, and
ganciclovir resistance resulting from truncated HSVtk formed from cryptic splice donor and
acceptor sites17.
We investigated the suitability of an alternative suicide gene, inducible caspase 9 (iCasp9)
18. iCasp9-mediated suicide is based on conditional dimerization of pro-apoptotic
molecules18,19, that are constructed from human proteins and therefore less likely to be
immunogenic. The mechanism of killing allows the safe use of ganciclovir, and is independent
of cell proliferation.
We now show the feasibility of engineering allodepleted T cells with an iCasp9 suicide gene
transfer, and demonstrate the functionality of the modified T cells, and the scalability of the
process.
MATERIALS AND METHODS
Generation of allodepleted T cells
Allodepleted cells were generated from healthy volunteers as previously described7,20. In
brief, peripheral blood mononuclear cells (PBMCs) from healthy donors were co-cultured with
irradiated recipient Epstein Barr virus (EBV)-transformed lymphoblastoid cell lines (LCL) at
responder-to-stimulator ratio of 40:1 in serum-free medium (AIM V; Invitrogen, Carlsbad,
CA). After 72 hours, activated T cells that expressed CD25 were depleted from the co-culture
by overnight incubation in RFT5-SMPT-dgA immunotoxin21. Allodepletion was considered
adequate if the residual CD3+CD25+ population was <1% and residual proliferation by 3H-
thymidine incorporation was <10%7.
Plasmid and retrovirus
SFG.iCasp9.2A.ΔCD19 consists of inducible caspase 9 (iCasp9) linked, via a cleavable 2A-
like sequence, to truncated human CD19 (ΔCD19)(Fig. 1A). iCasp9 consists of a human
FK506-binding protein (FKBP12; GenBank AH002 818) with an F36V mutation, connected
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via a Ser-Gly-Gly-Gly-Ser linker to human caspase 9 (CASP9; GenBank NM 001229)18. The
F36V mutation increases the binding affinity of FKBP12 to the synthetic homodimerizer,
AP20187 or AP190322. The caspase recruitment domain (CARD) has been deleted from the
human caspase 9 sequence because its physiological function has been replaced by FKBP12,
and its removal increases transgene expression and function18. The 2A-like sequence encodes
an 20 amino acid peptide from Thosea Asigna insect virus, which mediates >99% cleavage
between a glycine and terminal proline residue23, resulting in 19 extra amino acids in the C
terminus of iCasp9, and one extra proline residue in the N terminus of CD19. ΔCD19 consists
of full-length CD19 (GenBank NM 001770) truncated at amino acid 333 (TDPTRRF), which
shortens the intracytoplasmic domain from 242 to 19 amino acids, and removes all conserved
tyrosine residues that are potential sites for phosphorylation24,25.
A stable PG13 clone producing Gibbon ape leukemia virus (Gal-V) pseudotyped retrovirus
was made by transiently transfecting Phoenix Eco cell line (ATCC product #SD3444; ATCC,
Manassas, VA) with SFG.iCasp9.2A.ΔCD19. This produced Eco-pseudotyped retrovirus. The
PG13 packaging cell line (ATCC) was transduced three times with Eco-pseudotyped retrovirus
to generate a producer line that contained multiple SFG.iCasp9.2A.ΔCD19 proviral integrants
per cell. Single cell cloning was performed, and the PG13 clone that produced the highest titer
was expanded and used for vector production.
Retroviral transduction
Culture medium for T cell activation and expansion consisted of 45% RPMI 1640 (Hyclone,
Logan, UT), 45% Clicks (Irvine Scientific, Santa Ana, CA) and 10% fetal bovine serum (FBS;
Hyclone). Allodepleted cells were activated by immobilized anti-CD3 (OKT3; Ortho Biotech,
Bridgewater, NJ) for 48 hours before transduction with retroviral vector (Fig. 1B). In small-
scale experiments, non-tissue culture-treated 24-well plates (Becton Dickinson, San Jose, CA)
were coated with OKT3 1μg/ml for 2 to 4 hours at 37°C. Allodepleted cells were added at
1×106 cells per well. At 24 hours, 100U/ml of recombinant human interleukin-2 (IL-2)
(Proleukin; Chiron, Emeryville, CA) was added. Retroviral transduction was performed 48
hours after activation. Non-tissue culture-treated 24-well plates were coated with 3.5μg/cm2
recombinant fibronectin fragment (CH-296;Retronectin; Takara Mirus Bio, Madison, WI) and
the wells loaded twice with retroviral vector-containing supernatant at 0.5ml per well for 30
minutes at 37°C, following which OKT3-activated cells were plated at 5×105 cells per well in
fresh retroviral vector-containing supernatant and T cell culture medium at a ratio of 3:1,
supplemented with 100U/ml IL-2. Cells were harvested after 2 to 3 days and expanded in the
presence of 50U/ml IL-2.
Scaling-up production of gene-modified allodepleted cells
Scale-up of the transduction process for clinical application used non-tissue culture-treated
T75 flasks (Nunc, Rochester, NY), which were coated with 10ml of OKT3 1μg/ml or 10ml of
fibronectin 7μg/ml at 4°C overnight. We also used fluorinated ethylene propylene bags corona-
treated for increased cell adherence (2PF-0072AC, American Fluoroseal Corporation,
Gaithersburg, MD). Allodepleted cells were seeded in OKT3-coated flasks at 1×106 cells/ml.
100U/ml IL-2 was added the next day. For retroviral transduction, retronectin-coated flasks or
bags were loaded once with 10ml of retrovirus-containing supernatant for 2 to 3 hours. OKT3-
activated T cells were seeded at 1×106 cells/ml in fresh retroviral vector-containing medium
and T cell culture medium at a ratio of 3:1, supplemented with 100U/ml IL-2. Cells were
harvested the following morning and expanded in tissue-culture treated T75 or T175 flasks in
culture medium supplemented with 50 to 100U/ml IL-2 at a seeding density of 5 to 8×105 cells/
ml.
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CD19 immunomagnetic selection
Immunomagnetic selection for CD19 was performed 4 days after transduction. Cells were
labeled with paramagnetic microbeads conjugated to monoclonal mouse anti-human CD19
antibodies (Miltenyi Biotech, Auburn, CA) and selected on MS or LS columns in small scale
experiments and on a CliniMacs Plus automated selection device in large scale experiments.
CD19-selected cells were expanded for a further 4 days and cryopreserved on day 8 post
transduction. These cells were referred to as “gene-modified allodepleted cells”.
Immunophenotyping and pentamer analysis
Flow cytometric analysis (FACSCalibur and CellQuest software; Becton Dickinson) used the
following antibodies: CD3, CD4, CD8, CD19, CD25, CD27, CD28, CD45RA, CD45RO,
CD56 and CD62L. CD19-PE (Clone 4G7; Becton Dickinson) was found to give optimum
staining and was used in all analysis. Non-transduced control was used to set the negative gate
for CD19. An HLA-pentamer, HLA-B8-RAKFKQLL (Proimmune, Springfield, VA) was used
to detect T cells recognizing an epitope from EBV lytic antigen (BZLF1). HLA-A2-
NLVPMVATV pentamer was used to detect T cells recognizing an epitope from CMV-pp65
antigen.
Interferon-γ ELISPOT assay for anti-viral response
Interferon-γ ELISPOT for assessment of responses to EBV, CMV and adenovirus antigens
was performed as previously described20. Gene-modified allodepleted cells cryopreserved at
8 days post transduction were thawed and rested overnight in complete medium without IL-2
prior to use as responder cells. Cryopreserved PBMCs from the same donor were used as
comparators. Responder cells were plated in duplicate or triplicate in serial dilutions of
2×105, 1×105, 5×104 and 2.5×104 cells per well. Stimulator cells were plated at 1×105 per well.
For response to EBV, donor-derived EBV-LCLs irradiated at 40Gy were used as stimulators.
For response to adenovirus, donor-derived activated monocytes infected with Ad5f35
adenovirus were used. In brief, donor PBMCs were plated in X-Vivo 15 (Cambrex,
Walkersville, MD) in 24-well plates overnight, harvested the next morning, infected with
Ad5f35 at MOI of 200 for 2 hours, washed, irradiated at 30Gy, and used as stimulators. For
anti-CMV response, a similar process using Ad5f35 adenovirus encoding the CMV pp65
transgene (Ad5f35-pp65) at an MOI 5000 was used. Specific spot-forming units (SFU) were
calculated by subtracting SFU from responder-alone and stimulator-alone wells from test wells.
Response to CMV was the difference in SFU between Ad5f35-pp65 and Ad5f35 wells.
EBV-specific cytotoxicity
Gene-modified allodepleted cells were stimulated with 40Gy-irradiated donor-derived EBV-
LCL at a responder:stimulator ratio of 40:1. After 9 days, the cultures were restimulated at a
responder:stimulator ratio of 4:1. Restimulation was performed weekly as indicated. After two
or three rounds of stimulation, cytotoxicity was measured in a 4-hour 51Cr-release assay, using
donor EBV-LCL as target cells and donor OKT3 blasts as autologous controls. NK activity
was inhibited by adding 30-fold excess of cold K562 cells.
Induction of apoptosis with chemical inducer of dimerization, AP20187
Suicide gene functionality was assessed by adding a small molecule synthetic homodimerizer,
AP20187 (Ariad Pharmaceuticals; Cambridge, MA), at 10nM final concentration the day
following CD19 immunomagnetic selection. Cells were stained with annexin V and 7-amino-
actinomycin (7-AAD)(BD Pharmingen) at 24 hours and analyzed by flow cytometry. Cells
negative for both Annexin V and 7-AAD were considered viable, cells that were annexin V
positive were apoptotic, and cells that were both annexin V and 7-AAD positive were necrotic.
The percentage killing induced by dimerization was corrected for baseline viability as follows:
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Percentage killing = 100% - (%Viability in AP20187-treated cells ÷ %Viability in non-treated
cells).
Assessment of transgene expression following extended culture and reactivation
Cells were maintained in T cell medium containing 50U/ml IL-2 until 22 days after
transduction. A portion of cells was reactivated on 24-well plates coated with 1μg/ml OKT3
and 1μg/ml anti-CD28 (Clone CD28.2, BD Pharmingen, San Jose, CA) for 48 to 72 hours.
CD19 expression and suicide gene function in both reactivated and non-reactivated cells were
measured on day 24 or 25 post transduction.
In some experiments we also cultured the cells for 3 weeks post transduction but simulated
them with 30G-irradiated allogeneic PBMC at responder:stimulator ratio of 1:1. After 4 days
of co-culture, a portion of cells was treated with 10nM AP20187. Killing was measured by
annexin V/7-AAD staining at 24 hours, and the effect of dimerizer on bystander virus-specific
T cells was assessed by pentamer analysis on AP20187-treated and untreated cells.
Regulatory T cells
We analyzed CD4, CD25 and Foxp3 expression in gene-modified allodepleted cells using flow
cytometry. For human Foxp3 staining we used the eBioscience (San Diego, CA) staining set
with an appropriate rat IgG2a isotype control. These cells were co-stained with surface CD25-
FITC and CD4-PE. Functional analysis was performed by co-culturing CD4+25+ cells selected
after allodepletion and gene modification with carboxyfluorescein diacetate N-succinimidyl
ester (CFSE)-labeled autologous PBMC. CD4+25+ selection was performed by first depleting
CD8+ cells using anti-CD8 microbeads (Miltenyi Biotec, Auburn, CA), followed by positive
selection using anti-CD25 microbeads (Miltenyi Biotec, Auburn, CA). CFSE-labeling was
performed by incubating autologous PBMC at 2×107/ml in phosphate buffered saline
containing 1.5μM CFSE for 10 minutes. The reaction was stopped by adding an equivalent
volume of FBS and incubating for 10 minutes at 37°C. Cells were washed twice before use.
We stimulated CFSE-labeled PBMCs with OKT3 500ng/ml and 40G-irradiated allogeneic
PBMC feeders at PBMC: allogeneic feeders ratio of 5:1. We cultured the cells with or without
an equal number of autologous CD4+25+ gene-modified allodepleted cells. After 5 days of
culture, cell division was analyzed by flow cytometry; CD19 was used to gate out non-CFSE-
labeled CD4+CD25+ gene-modified T cells.
Statistical analysis
Paired, 2-tailed Student’s t test was used to determine the statistical significance of differences
between samples. All data are represented as mean ± 1 standard deviation.
RESULTS
Selectively allodepleted T cells could be efficiently transduced with iCasp9 and expanded
Selective allodepletion was performed in accordance with procedures established for our
recently completed clinical protocol7, by co-culturing 3/6 to 5/6 HLA-mismatched PBMC and
lymphoblastoid cell lines (LCL). RFT5-SMPT-dgA immunotoxin was applied after 72 hours
of co-culture and reliably produced allodepleted cells with <10% residual proliferation (mean
4.5 ± 2.8%; range 0.74 to 9.1%; 10 experiments) and containing <1% residual CD3+CD25+
cells (mean 0.23 ± 0.20%; range 0.06 to 0.73%; 10 experiments), thereby fulfilling the release
criteria for selective allodepletion, and serving as starting materials for subsequent
manipulation.
Allodepleted cells activated on immobilized OKT3 for 48 hours could be efficiently transduced
with Gal-V pseudotyped retrovirus vector encoding SFG.iCasp9.2A.ΔCD19. Transduction
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efficiency assessed by FACS analysis for CD19 expression 2 to 4 days after transduction was
53% ± 8%, with comparable results for small-scale (24-well plates) and large-scale (T75 flasks)
transduction (55 ± 8% versus 50% ± 10% in 6 and 4 experiments, respectively). Cell numbers
contracted in the first 2 days following OKT3 activation such that only 61 ± 12% (range 45 to
80%) of allodepleted cells were recovered on the day of transduction (Fig. 2). Thereafter, the
cells showed significant expansion, with a mean 94 ± 46 -fold expansion (range 40 to 153)
over the subsequent 8 days, resulting in a net 58 ± 33 -fold expansion. Cell expansion in both
small- and large-scale experiments was similar, with net expansion of 45 ± 29 fold (range 25
to 90) in 5 small-scale experiments and 79 ± 34 fold (range 50 to 116) in 3 large-scale
experiments.
ΔCD19 enables efficient and selective enrichment of transduced cells on immunomagnetic
columns
The efficiency of suicide gene activation will depend not only on the functionality of the suicide
gene itself, but also on the selection system used to enrich for gene-modified cells. Due to
limitations of selectable markers currently in use, we investigated whether ΔCD19 enabled the
selection of gene-modified cells with sufficient purity and yield, and whether selection had any
deleterious effects on subsequent cell growth. Small-scale selection was performed according
to manufacturer’s instruction; however, we found that large-scale selection was optimum when
we used 10μl of CD19 microbeads per 1.3×107 cells. FACS analysis was performed at 24 hours
after immunomagnetic selection to minimize interference from anti-CD19 microbeads. The
purity of the cells after immunomagnetic selection was consistently greater than 90%: mean
percentage of CD19+ cells was 98.3 ± 0.5% (n=5) in small-scale selections and 97.4 ± 0.9%
(n=3) in large-scale CliniMacs selections (Fig.3). The absolute yield of small- and large-scale
selections were 31 ± 11 % and 28 ± 6% respectively; after correction for transduction efficiency,
the mean recovery of transduced cells was 54 ± 14 % in small-scale and 72 ± 18 % in large-
scale selections. The selection process did not have any discernable deleterious effect on
subsequent cell expansion: in 4 experiments, the mean cell expansion over 3 days following
CD19 immunomagnetic selection was 3.5 fold for the CD19 positive fraction versus 4.1 fold
for non-selected transduced cells (p=0.34) and 3.7 fold for non-transduced cells (p=0.75).
Immunophenotype of gene-modified allodepleted cells
We immunophenotyped the final cell product (gene-modified allodepleted cells that had been
cryopreserved 8 days after transduction). This final cell product contained both CD4 and CD8
cells, with CD8 cells predominant (Table 1) at 62% ±11% CD8+ versus 23% ± 8% CD4+. The
majority of cells were CD45RO+ and had the surface immunophenotype of effector memory
T cells. Expression of memory markers, including CD62L, CD27 and CD28, was
heterogeneous. Approximately 24% of cells expressed CD62L, a lymph node-homing
molecule predominantly expressed on central memory cells.
Gene-modified allodepleted cells retained antiviral repertoire and functionality
The ability of end-product cells to mediate antiviral immunity was assessed by interferon-γ
ELISPOT, cytotoxicity assay, and pentamer analysis. These cryopreserved gene-modified
allodepleted cells were used in all analyses, since they were representative of the product we
propose to administer in the clinical study. Interferon-γ secretion in response to adenovirus,
CMV or EBV antigens presented by donor cells was preserved although there was a trend
towards reduced anti-EBV response in gene-modified allodepleted cells versus unmanipulated
PBMC (Fig. 4A).
Cytotoxicity was assessed using donor-derived EBV-LCL as targets. Gene-modified
allodepleted cells that had undergone 2 or 3 rounds of stimulation with donor-derived EBV-
LCL could efficiently lyse virus-infected autologous target cells (Fig. 4B). Since EBV-LCLs
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were used as antigen-presenting cells during selective allodepletion, it was possible that EBV-
specific T cells could be significantly depleted when the donor and recipient were
haploidentical. We therefore included three experiments using unrelated HLA-haploidentical
donor-recipient pairs, and showed that cytotoxicity against donor-derived EBV-LCL was
retained. The results were corroborated by pentamer analysis for T cells recognizing HLA-B8-
RAKFKQLL, an EBV lytic antigen (BZLF1) epitope, in two informative donors following
allodepletion against HLA-B8 negative haploidentical recipients (Fig 4C). The RAK-pentamer
positive population was retained and could expand following stimulation with donor EBV-
LCL. Together, these results provided evidence that gene-modified allodepleted cells retained
significant anti-viral functionality.
Regulatory T cells in the Gene-modified allodepleted cell population
We used flow cytometry and functional analysis to discover whether regulatory T cells was
retained in our allodepleted, gene modified, T cell product. We found a Foxp3+ CD4+25+
population (Fig. 5A), and following immunomagnetic separation, the CD4+CD25+ enriched
fraction demonstrated suppressor function when co-cultured with CFSE-labeled autologous
PBMC in the presence of OKT3 and allogeneic feeders (Fig. 5B). Hence, allodepleted T cells
may re- acquire regulatory phenotype even after exposure to a CD25 depleting immunotoxin.
Gene-modified allodepleted cells were efficiently and rapidly eliminated by addition of
chemical inducer of dimerization
The day following immunomagnetic selection, 10nM of the chemical inducer of dimerization,
AP20187, was added to induce apoptosis, which appeared within 24 hours. FACS analysis
with annexin V and 7-AAD staining at 24 hours showed that only 5.5 ± 2.5% of AP20187-
treated cells remained viable, whereas 81.0 ± 9.0 % of untreated cells were viable (Fig.6A).
Killing efficiency after correction for baseline viability was 92.9 ± 3.8%. Large-scale CD19
selection produced cells that were killed with similar efficiency as small-scale selection: mean
viability with and without AP20187, and percentage killing, in large and small scale were 3.9%,
84.0%, 95.4% (n=3) and 6.6%, 79.3%, 91.4% (n=5) respectively. AP20187 was non-toxic to
non-transduced cells: viability with and without AP20187 were 86 ± 9% and 87 ± 8%
respectively (n=6).
Transgene expression and function decreased with extended culture but were restored upon
cell reactivation
To assess the stability of transgene expression and function, we maintained cells in T cell
culture medium and low dose IL-2 (50U/ml) until 24 days after transduction. By day 24, surface
CD19 expression fell from 98 ± 1% to 88 ± 4% (p<0.05) with a parallel decrease in mean
fluorescence intensity (MFI) from 793 ± 128 to 478 ± 107 (p<0.05) (Fig.6B). Similarly, there
was a significant reduction in suicide gene function: residual viability was 19.6 ± 5.6%
following treatment with AP20187; after correction for baseline viability of 54.8 ± 20.9%, this
equated to killing efficiency of only 63.1 ± 6.2%.
To discover whether the decrease in transgene expression with time was due to reduced
transcription following T cell quiescence or to elimination of transduced cells, we reactivated
a portion of cells on day 22 post transduction with OKT3 and anti-CD28 antibody. At 48 to
72 hours (day 24 or 25 post transduction), OKT3/aCD28-reactivated cells had significantly
higher transgene expression than non-reactivated cells. CD19 expression increased from 88 ±
4% to 93 ± 4% (p <0.01) and CD19 MFI increased from 478 ± 107 to 643 ± 174 (p<0.01).
More importantly, suicide gene function also increased significantly from 63.1 ± 6.2% killing
efficiency to 84.6 ± 8.0% (p<0.01). Furthermore, killing efficiency was completely restored if
the cells were immunomagnetically sorted for the activation marker CD25: killing efficiency
of CD25 positive cells was 93.2 ± 1.2%, which was the same as killing efficiency on day 5
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post transduction (93.1 ± 3.5%)(Fig. 6C). Killing of the CD25 negative fraction was 78.6 ±
9.1%.
Of note, virus-specific T cells are spared when dimerizer is used to deplete gene-modified cells
that have been re-activated with allogeneic PBMC, rather than by non-specific mitogenic
stimuli. After 4 days reactivation with allogeneic cells, Figs 7A and B show that treatment with
AP20187 spares (and thereby enriches) viral reactive subpopulations, as measured by the
proportion of T cells reactive with HLA pentamers specific for peptides derived from EBV
and CMV.
DISCUSSION
We have demonstrated the feasibility of engineering allogeneic T cells with two distinct safety
mechanisms, selective allodepletion and suicide gene-modification. In combination, these
modifications should enable addback of substantial numbers of T cells with anti-viral and anti-
tumor activity, even after haploidentical transplantation. Our data show that the suicide gene,
iCasp9, functions efficiently (>90% apoptosis after treatment with dimerizer) and that down-
modulation of transgene expression that occurred with time was rapidly reversed upon T cell
activation, as would occur when alloreactive T cells encountered their targets. We also showed
that ΔCD19 was a suitable selectable marker that enabled efficient and selective enrichment
of transduced cells to >90% purity, and that these manipulations had no discernable effects on
the immunological competence of the engineered T cells with retention of antiviral activity,
and regeneration of a CD4+CD25+Foxp3+ population with Treg activity.
Given that the overall functionality of suicide genes depends on both the suicide gene itself
and the marker used to select the transduced cells, translation into clinical use requires
optimization of both components, and of the method used to couple expression of the two
genes. The two most widely used selectable markers in clinical practice each have drawbacks.
Neomycin phosphotransferase (neo) encodes a potentially immunogenic foreign protein and
requires a 7-day culture in selection medium, which not only increases the complexity of the
system, but is also potentially damaging to virus-specific T cells26. The most widely used
surface selection marker is ΔLNGFR, but recent report of leukemia in a mouse model raises
concerns regarding its oncogenic potential27, despite its apparent clinical safety 28.
Furthermore, ΔLNGFR selection is not widely available, because it is used almost exclusively
in gene therapy. A number of alternative selectable markers have been suggested. CD34 has
been well-studied in vitro29,30, but the steps required to optimize a system designed primarily
for selection of rare hematopoietic progenitors, and more critically, the potential for altered in
vivo T cell homing31, make CD34 sub-optimal for our purpose. As an alternative marker, we
used ΔCD19, since clinical grade CD19 selection is readily available as a method for B-cell
depletion of stem cell autografts. We demonstrated that ΔCD19 enrichment could be performed
with high purity and yield and, more importantly, the selection process had no discernable
effect on subsequent cell growth and functionality.
The effectiveness of suicide gene activation in ΔCD19-selected iCasp9 cells compared very
favorably to that of neo- or ΔLNGFR-selected cells transduced to express the HSVtk gene.
The earlier generations of HSVtk constructs provided 80-90% suppression of 3H-thymidine
uptake14,32,33 and showed similar reduction in killing efficiency upon extended in vitro
culture33, but were nonetheless clinically efficacious. Complete resolution of both acute and
chronic GVHD has been reported with as little as 80% in vivo reduction in circulating gene-
modified cells. These data supported the hypothesis that transgene down-modulation seen in
vitro is unlikely to be an issue because activated T cells responsible for GVHD will upregulate
suicide gene expression and will therefore be selectively eliminated in vivo14. Whether this
effect is sufficient to allow retention of virus- and leukemia-specific T cells in vivo remains to
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be tested in a clinical setting. By combining in vitro selective allodepletion prior to suicide
gene modification, we hope that the need to activate the suicide gene mechanism will be
significantly reduced, thereby maximizing the benefits of addback T cell.
The high efficiency of iCasp9-mediated suicide seen in vitro has been replicated in vivo. In a
SCID mouse-human xenograft model, more than 99% of iCasp9-modified T cells were
eliminated after a single dose of dimerizer18. Safety testing has been performed on healthy
human volunteers using AP1903, which has extremely close functional and chemical
equivalence to AP20187, and would be used in a proposed clinical application. Maximal
plasma level of 10 to 1275ng/ml AP1903 (equivalent to 7 to 892nM) was attained over a
0.01mg/kg to 1.0mg/kg dose range administered as a 2-hour intravenous infusion34. There
were no significant adverse effects. After allowing for rapid plasma redistribution, the
concentration of dimerizer used in vitro remains readily achievable in vivo.
We believe iCasp9 will prove to have several advantages over HSVtk, including the ability to
use ganciclovir and related drugs without causing inadvertent T cell destruction, and a reduced
risk of destructive immune responses against transduced cells since the iCasp9 is almost
entirely human-derived. Although both our selectable marker (ΔCD19) and our suicide gene
(iCasp9) are of human origin, one potential limitation of our approach is that linkage of
expression of the selectable marker to the suicide gene uses a 2A-like cleavable peptide which
is of non-human origin. However, this product is only 20 amino acids long, and is therefore
less likely to be immunogenic than entirely non-human proteins such as neo or HSVtk.
It is essential to define the culture conditions that are optimal for maintaining the
immunological competence of suicide gene-modified T cells, since phenotype, repertoire and
functionality can all be affected by the stimulation used for polyclonal T cell activation35,
36, the method for selection of transduced cells26, and duration of culture37. The addition of
CD28 co-stimulation and the use of cell-sized paramagnetic beads to generate gene modified-
cells that more closely resemble unmanipulated PBMC in terms of CD4:CD8 ratio, and
expression of memory subset markers including lymph node homing molecules CD62L and
CCR7, have been proposed as methods for improving the in vivo functionality of gene-
modified T cells35,36. CD28 co-stimulation has also been reported to increase the efficiency
of retroviral transduction and expansion35,36. Interestingly however, we found that the
addition of CD28 co-stimulation had no impact on transduction of allodepleted cells (data not
shown), and the degree of cell expansion seen in our study was higher compared to the anti-
CD3 alone arm in these studies. Furthermore, iCasp9-modified allodepleted cells retained
significant anti-viral functionality, and approximately one fourth retained CD62L expression.
There was also regeneration of CD4+CD25+Foxp3+ regulatory T cells. The allodepleted cells
we used as starting material for T cell activation and transduction may have been less sensitive
to the addition of anti-CD28 antibody as co-stimulation. CD25-depleted PBMC / EBV-LCL
co-cultures contained T cells and B cells that already express CD86 at significantly higher level
than unmanipulated PBMC (data not shown) and may themselves provide co-stimulation. In
addition, it has been reported that depletion of CD25+ regulatory T cells prior to polyclonal T
cell activation with anti-CD3 enhances the immunological competence of the final T cell
product37. In order to minimize the effect of in vitro culture and expansion on functional
competence, we used a relatively brief culture period whereby cells were expanded for a total
of 8 days post-transduction with CD19-selection being performed on day 4.
Finally, we have demonstrated that we can scale up production sufficiently to treat adult
patients at doses of up to 107 cells/kg: allodepleted cells can be activated and transduced at
4×107cells per flask, and a minimum of 8-fold return of CD19-selected final cell product can
be obtained on day 8 post-transduction, to produce at least 3×108 allodepleted gene-modified
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cells per original flask. The increased culture volume is readily handled in additional flasks or
bags.
The allodepletion and iCasp9-modification we describe should significantly improve the safety
of adding back T cells, particularly after haploidentical stem cell allografts. This should in turn
enable greater dose-escalation, with a higher chance of producing a hoped for anti-leukemia
effect. We will explore this possibility in a clinical study of our modified allodepleted T cells.
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Figure 1. Generation of iCasp9 suicide gene-modified selectively allodepleted cells
(A) Structure of SFG.iCasp9.2A.ΔCD19. The transgene consists of a suicide gene, inducible
caspase 9 (iCasp9), and a selectable marker, truncated CD19 (ΔCD19), linked by a 2A-like
sequence, which encodes a cleavable peptide. iCasp9 consists of a drug-binding domain
(FKBP12-F36V) connected via a short linker (SGGGS) to human caspase 9. (B) Overview of
the production process. Selective allodepletion was performed by co-culturing donor PBMC
with recipient EBV-LCL to activate alloreactive cells: activated cells expressed CD25 and
were subsequently eliminated by anti-CD25 immunotoxin. The allodepleted cells were
activated by OKT3 and transduced with the retroviral vector 48 hours later. Immunomagnetic
selection was performed on day 4 of transduction; the positive fraction was expanded for a
further 4 days and cryopreserved.
Tey et al. Page 13
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2007 October 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Allodepleted cells could be successfully expanded following transduction
◆ denotes large-scale experiments performed in flasks and bags (n=3), ○ denotes small-scale
experiments performed in 24-well plates (n=5). Error bars indicate standard deviation.
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Figure 3. Suicide gene-modified cells could be enriched to high purity by CD19 immunomagnetic
selection
CD19 immunomagnetic selection was performed on day 4 post transduction using CliniMacs
Plus automated selection device. Shown here are FACS analyses performed 2 days after
immunomagnetic selection. Filled lines indicate CD19-PE; unfilled lines indicate isotype
control.
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Figure 4. Gene-modified allodepleted cells retained anti-viral repertoire and functionality
(A) Interferon-γ secretion in response to viral antigens was assessed by ELISPOT in 4 pairs
of unmanipulated PBMC and gene-modified allodepleted cells (GMAC). Adenovirus and
CMV antigens were presented by donor-derived activated monocytes through infection with
Ad5f35 null vector and Ad5f35-pp65 vector, respectively. EBV antigens were presented by
donor EBV-LCL. Number of spot-forming units (SFU) were corrected for stimulator- and
responder-alone wells. Only three of four donors were evaluable for CMV response, one
seronegative donor was excluded. Horizontal bars = median. (B) Cytotoxicity assay. Gene-
modified allodepleted cells were stimulated with donor EBV-LCL for 2 or 3 cycles. 51Cr release
assay was performed using donor-derived EBV-LCL and donor OKT3 blasts as targets. NK
activity was blocked with 30-fold excess cold K562. Left panel shows results from 5
independent experiments using totally or partially mismatched donor-recipient pairs. Right
panel shows results from 3 experiments using unrelated HLA haploidentical donor-recipient
pairs. Error bars indicate standard deviation. (c) The frequency of T cells specific for HLA-B8-
RAKFKQLL, an epitope from an EBV lytic antigen (BZLF1), was analyzed. Unmanipulated
PBMC were used as comparators. The RAK-pentamer positive population was retained in
gene-modified allodepleted cells and could be expanded following several rounds of in vitro
stimulation with donor-derived EBV-LCL. Percentages indicate percentage of pentamer
positive cells within CD8 population.
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Figure 5. Regulatory T cells could be isolated from gene-modified end-product cells despite initial
allodepletion using CD25-immunotoxin
(A) Foxp3 expression. A small population of CD4+CD25+Foxp3+ cells was detectable. (B)
Functional assay. Donor-derived PBMC was labeled with CFSE and stimulated with OKT3
and allogeneic feeders. CD4+CD25+ cells were immunomagnetically selected from the gene-
modified cell population and added at 1:1 ratio to test wells. Flow cytometry was performed
after 5 days. Gene-modified T cells were gated out by CD19 expression. The addition of
CD4+CD25+ gene-modified cells (bottom panel) significantly reduced cell proliferation.
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Figure 6. Gene-modified allodepleted cells were rapidly and efficiently eliminated by AP20187.
Transgene expression and killing efficiency diminished with extended culture but were completely
restored upon T cell reactivation
(A) The day after immunomagnetic selection, cells were treated with 10nM dimerizer
(AP20187). FACS analysis for annexin V and 7-AAD was performed at 24 hours. The
percentages of viable cells are indicated in the plots. AP20187 resulted in >90% killing of
transduced cells but had no effect on non-transduced controls. Results are representative of 3
large-scale experiments. (B) Transduced cells were maintained in culture for 22 days post
transduction in low dose IL-2 (50U/ml). A portion of cells was then reactivated with OKT3/
anti-CD28. CD19 expression was analyzed by flow cytometry 48 to 72 hours later, and suicide
gene function was assessed by treatment with 10nM AP20187. Results shown are for cells
from day 5 post transduction (ie, 1 day after CD19 selection) and day 24 post transduction,
with or without 48-72 hours of reactivation (5 experiments). In 2 experiments, CD25 selection
was performed after OKT3/aCD28 activation to further enrich activated cells. Error bars
represent standard deviation. * indicates p<0.05 when compared to cells from day 5 post
transduction. (C) Representative FACS plots showing the effect of extended culture and T cell
activation on suicide gene function. Greater than 90% of activated CD25 positive T cells were
killed by AP20187
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Figure 7. Viral-specific T cells were partially retained after treatment of allostimulated cells with
dimerizer
Gene-modified allodepleted cells were maintained in culture for 3 weeks post-transduction to
allow transgene down-modulation. Cells were stimulated with allogeneic PBMC for 4 days,
following which a portion was treated with 10nM AP20187. The frequency of (A) EBV-
specific T cells and (B) CMV-specific T cells were quantified by pentamer analysis before
allostimulation, after allostimulation, and after treatment of allostimulated cells with dimerizer.
The percentage of virus-specific T cells decreased after allostimulation. Following treatment
with dimerizer, virus-specific T cells were partially and preferentially retained.
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Table 1
Comparison of immunophenotype of gene-modified allodepleted cells and unmanipulated PBMCa
Unmanipulated
PBMC
(mean % ± SD)
Gene-modified
allodepleted cells
(mean % ± SD)
T cells: Total CD3+ 82 ± 6 95 ± 6 NS
 CD3+ 4+ 54 ± 5 23 ± 8 p < 0.01
 CD3+ 8+ 26 ± 9 62 ± 11 p < 0.001
NK cells: CD3- 56+ 6 ± 3 2 ± 1 NS
Memory phenotype
 CD45RA+ 66 ± 3 10 ± 5 p<0.001
 CD45RO+ 26 ± 2 78 ± 7 p<0.001
 CD45RA- CD62L+ 19 ± 1 24 ± 7 NS
 CD45RA- CD62L- 9 ± 1 64 ± 7 p<0.001
 CD27+ CD28+ 67 ± 7 19 ± 9 p<0.001
 CD27+ CD28- 7 ± 3 9 ± 4 NS
 CD27- CD28+ 4 ± 1 19 ± 8 p<0.05
 CD27- CD28- 22 ± 8 53 ± 18 p<0.05
a
NS not significant, SD standard deviation
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